Olaparib Maintenance Therapy in PSR Ovarian Cancer: Phase III L-MOCA Final Survival and Safety Analyses
Introduction
The use of Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy in platinum-sensitive recurrent ovarian cancer (PSROC) differs between countries. In Asian populations, limited clinical trial data and insufficient biomarker studies make its benefits uncertain.
Aim
The study evaluated the efficacy and safety of oral olaparib at a dose of 300 mg (tablet formulation) twice daily as maintenance monotherapy in patients with PSR OC who had achieved a complete or partial response to their most recent platinum-based chemotherapy.
Patient Profile
- Women aged ≥18 years with relapsed high-grade serous or high-grade endometrioid epithelial ovarian, primary peritoneal, or fallopian tube carcinoma, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1.
- Who had previously received ≥2 prior lines of platinum-based chemotherapy and demonstrated platinum-sensitive disease, defined as disease progression occurring ≥6 months after the last platinum dose.
Methods
- Prospective, open-label, single-arm, phase IIIb L-MOCA study.
Study Endpoints
- Primary endpoint: Progression-free survival (PFS) per RECIST v1.1
- Secondary endpoints
- Overall survival (OS), time to second progression (PFS2), time to first subsequent treatment or death (TFST), time to study treatment discontinuation or death (TDT), and time to second subsequent treatment or death (TSST).
- Prespecified exploratory analyses by BRCA mutation and HRD status, and by number of prior treatment lines.
- Safety endpoints: incidence and severity of treatment-emergent and serious AEs
Results
After a median follow-up of 73.4 months, the median OS (mOS) reached 51.0 months (95% CI, 42.7 to 56.1).
- Olaparib demonstrated prolonged survival benefit, with improved outcomes notably in BRCAm and HRD-positive patients, though benefit was observed regardless of biomarker status.
- The mOS was 64.4 months (49.9 to not reach [NR]) in BRCA-mutated patients and 40.9 months (33.3 to 51.0) in BRCA wild-type patients.
- The mOS was 54.4 months (42.5 to NE) in HRD-positive patients and 34.8 months (28.3 to 46.6) in HRD-negative patients.
Table 1: Survival outcomes by BRCA mutation and HRD status
|
Group |
Median OS (months) |
95% CI |
|
Overall population |
51.0 |
42.7–56.1 |
|
BRCAm |
64.4 |
49.9–NR |
|
BRCAwt |
40.9 |
33.3–51.0 |
|
Germline BRCAm |
57.6 |
49.9–NR |
|
Somatic BRCAm |
NR |
29.4–NR |
|
HRD+ |
54.4 |
42.5–NR |
|
HRD– |
34.8 |
28.3–46.4 |
|
HRD+/BRCAm |
64.4 |
43.5–NR |
|
HRD+/BRCAwt |
42.5 |
32.8–73.0 |
- Earlier-line treatment was associated with improved survival outcomes
Table 2: Survival outcomes by Prior lines of anticancer treatment
|
Category |
Median OS (months) |
95% CI |
|
2 L |
54.6 |
43.3–67.5 |
|
>2 L |
39.5 |
~30.1–53.6 |
|
BRCAm (2L) |
NR |
51.9–NR |
|
BRCAwt (2L) |
43.1 |
33.3–55.6 |
|
BRCAm (>2L) |
44.6 |
29.3–NR |
|
BRCAwt (>2L) |
38.0 |
24.9–51.0 |
2L, second line; NR, not reached; wt, wildtype
- Updated secondary time-to-event endpoints, including PFS2, TFST, and TSST, further supported durable disease control beyond first progression
Table 3: Key Efficacy and Time-to-Event Outcomes
|
Endpoint |
Median (months) |
36 months (%) |
60 months (%) |
72 months (%) |
|
PFS |
16.2 |
— |
— |
— |
|
TDT |
13.7 |
15.2 |
8.5 |
7.5 |
|
TFST |
18.3 |
30.0 |
21.5 |
20.9 |
|
PFS2 |
29.4 |
39.2 |
24.4 |
22.5 |
|
TSST |
34.0 |
47.9 |
32.7 |
32.1 |
PFS: Progression-Free Survival ;TDT: Time to Study Treatment Discontinuation or Death; TFST: Time to First Subsequent Treatment or Death; PFS2: Time to Second Progression; TSST: Time to Second Subsequent Treatment or Death ; —: Not reported / not applicable
Safety
- No new safety signals were identified compared to the primary L-MOCA report.
- Myelodysplastic syndrome and acute myeloid leukemia (MDS/AML) occurred in 1.3% of patients, and no additional cases were identified after approximately four additional years of follow-up beyond the primary analysis.
Table 3 : Safety Outcomes
|
Any TEAEs |
98.7% |
|
Grade ≥3 TEAEs |
49.1% |
|
Serious TEAEs |
26.8% |
|
Dose adjustments |
63.8% |
|
Discontinuation |
12.9% |
|
MDS/AML |
1.3% |
TEAE, treatment emergent adverse event.
Conclusion
Long-term follow-up from the L-MOCA study demonstrated that olaparib maintenance monotherapy provides durable survival benefits and delayed disease progression, with a manageable safety profile in Asian PSROC patients, irrespective of BRCA or HRD status.
Reference
J. Ovarian. Res.









